← Back to Search

Flavanol

Cocoa Flavanols for Memory Loss

N/A

Waitlist Available

Led By Richard P. Sloan, PhD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age between 50 and 69 years, both inclusive

Healthy Male or Female subjects. (Females must be post-menopausal)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial will test the effect of a cocoa-derived dietary flavanol on brain structures and cognitive outcomes in healthy participants, age 50-69.

Who is the study for?

This trial is for healthy individuals aged 50-69, with a BMI of 18.0-35 kg/m². Participants must be able to consent, post-menopausal if female, and not have significant health issues or allergies. They shouldn't be on unusual diets, hormone therapies, pregnant/lactating recently, or using certain medications.Check my eligibility

What is being tested?

The study tests the effects of cocoa-derived flavanols (650 mg) versus a placebo on brain function and inflammation over 12 weeks in older adults. It's randomized and controlled: participants don't choose which group they're in.See study design

What are the potential side effects?

Potential side effects are not specified but may include typical reactions to dietary supplements such as digestive discomfort or allergic reactions for those sensitive to cocoa products.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 69 years old.

Select...

I am a healthy individual. If female, I am post-menopausal.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

HMGB1

Secondary outcome measures

NFkB

TNFa

Other outcome measures

ModBent

ModRey

multiple cognitive domains

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: 650 mg of Cocoapro flavanolsActive Control1 Intervention

Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.

Group II: 0mg Cocoapro flavanolsPlacebo Group1 Intervention

Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor

1,431 Previous Clinical Trials

2,460,687 Total Patients Enrolled

9 Trials studying Inflammation

13,853 Patients Enrolled for Inflammation

National Institute on Aging (NIA)NIH

1,668 Previous Clinical Trials

28,004,918 Total Patients Enrolled

21 Trials studying Inflammation

4,438 Patients Enrolled for Inflammation

New York State Psychiatric InstituteLead Sponsor

475 Previous Clinical Trials

153,761 Total Patients Enrolled

4 Trials studying Inflammation

871 Patients Enrolled for Inflammation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Would I be able to help test this new medication?

"Eligible participants for this study must be aged 50 to 69, experience inflammation, and there can only be a maximum of 146 people in the trial."

Answered by AI

How many people fit the requirements to enroll in this research?

"That is accurate. The clinical trial, which is currently recruiting, was posted on January 1st, 2019 and was last updated on July 1st, 2022. They are looking for a total of 146 patients at a single site."

Answered by AI